Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subpopulation analysis of the phase 3 ARASENS study. This is an ASCO Meeting ...
Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...
Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...
Dysphagia in cancers of the lip, oral cavity, and pharynx patients: Impact on cachexia, hospitalization, and racial disparities on outcomes. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Researchers in Class of 1942 Professor of Chemistry Matthew D. Shoulders' lab have uncovered a sinister hidden mechanism that ...
A Northwestern Medicine-led study published in the Journal of Clinical Investigation has uncovered why older individuals with ...
The safety population consisted of 109 patients treated with at least one dose of rezatapopt 2000 mg daily as monotherapy. Median number of prior lines of systemic therapy was three (range: 1-10) The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results